LENZ Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
On February 20, 2026, Evert Schimmelpennink, our Chief Executive Officer, terminated a previously disclosed 10b5-1 trading plan that was intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and was adopted on August 11, 2025. The 10b5-1 trading plan provided for the sale of up to 225,000 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Schimmelpennink. No shares were sold under the plan prior to its termination.
During our last fiscal quarter, none of our other directors or officers, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.